Developmental stage modulates the prognostic impact of RAS pathway mutations in AML patients undergoing Allo-HSCT. Yuan X, Wu Y, Wang Y, Wu J, et al. Ann Hematol 2025;104:5359-5369.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Yuan X, Wu Y, Wang Y, Wu J, et al. Developmental stage modulates the prognostic impact of RAS pathway mutations in AML patients undergoing Allo-HSCT. Ann Hematol 2025;104:5359-5369.
PMID: 41134337